13.5858  -0.244 (-1.77%)		11-11 11:10
Open: 13.44 High: 13.65 Volume: 432		Pre. Close: 13.83 Low: 13.32 Market Cap: 6,718(M)

Short term
Mid term
Targets	6-month :	20.05	1-year :	23.36
Resists	First :	17.17	Second :	20
Pivot price	14.96
Supports	First :	12.6	Second :	10.48
MAs	MA(5) :	13.32	MA(20) :	15.57
	MA(100) :	15.28	MA(250) :	8.76
MACD	MACD :	-0.9	Signal :	-0.5
%K %D	K(14,3) :	16.8	D(3) :	13.6
RSI	RSI(14): 39.5
52-week	High :	83.59	Low :	0.09

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ RGC ] has closed above bottom band by 25.8%. Bollinger Bands are 56% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 77 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	14.89 - 15	15 - 15.08
Low:	13.31 - 13.41	13.41 - 13.49
Close:	13.69 - 13.86	13.86 - 13.98

Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.

Fri, 07 Nov 2025
Can Regencell (RGC) Balance Reduced Losses With Going Concern Uncertainty in Its Strategic Outlook? - simplywall.st

Tue, 04 Nov 2025
Regencell Bioscience Holdings (NasdaqCM:RGC): Examining Valuation Following Narrower Net Loss and Ongoing Volatility - simplywall.st

Tue, 04 Nov 2025
Regencell Bioscience (NASDAQ:RGC) Shares Down 9.5% - Here's Why - MarketBeat

Fri, 17 Oct 2025
Regencell Bioscience (NASDAQ:RGC) Shares Gap Down - Here's What Happened - MarketBeat

Tue, 07 Oct 2025
Regencell Goes From Collapse to Comeback: RGC Stock Targets $30 After $20 Break - FXLeaders

Wed, 01 Oct 2025
Regencell Bioscience Holdings Limited (RGC) Added to S&P Global BMI Index Amid Positive ADHD/ASD Trial Results - Yahoo Finance

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Shares Out	494 (M)
Shares Float	18 (M)
Held by Insiders	96.1 (%)
Held by Institutions	0.1 (%)
Shares Short	1,360 (K)
Shares Short P.Month	1,680 (K)

EPS	-0.01
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-30.7 %
Return on Equity (ttm)	-47.8 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-0.01
Qtrly Earnings Growth	0 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	0 (M)

PE Ratio	-1344
PEG Ratio	0
Price to Book value	1344
Price to Sales	0
Price to Cash Flow	0

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.